Trial Profile
A phase I/IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of Aramchol in children with non-alcoholic fatty liver disease
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2016
Price :
$35
*
At a glance
- Drugs Icomidocholic acid (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; Pharmacokinetics
- Acronyms ARTISAN
- 03 Oct 2016 New trial record
- 23 Sep 2016 According to a Galmed Pharmaceuticals media release, this trial is planned to be initiated in the first half of 2017. Galmed signed an investigator-initiated clinical trial agreement with the University of California, San Diego, School of Medicine for this trial.